EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators
This article was originally published in The Pink Sheet Daily
Executive Summary
Remission maintenance drug should receive formal EC approval within 67 days; new U.S. filing planned for 2009.
You may also be interested in...
Maxim Seeks Ceplene Development Partner After FDA Request For More Data
FDA indicates that approval of Ceplene for the treatment of acute myeloid leukemia would require confirmatory Phase III trial, Maxim says. The company previously withdrew an NDA for use of the oncologic in advanced malignant melanoma.
Pharmos Names Meer CFO
Pharmos has tapped former Schein VP James Meer as its chief financial officer.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.